A new test that could provide a diagnosis of the Zika virus in less than 30 minutes in doctors’ and other health care providers’ offices has received funding from the Department of Health and Human Services.

In a news release, the agency said within the next year, the Biomedical Advanced Research and Development Authority (BARDA) — a part of the HHS response to health care needs — plans to provide $5.9 million for the new initiative. It will pay close attention to the sensitivity and specificity of the test, steps that must be followed to secure Food and Drug Administration approval.

Close

Related: Looming Zika Infant Epidemic

The contract could be extended for up to a total of three years and cost up to $13.2 million.

“Developing safe and effective diagnostic tests, vaccines, and blood screens are essential in curbing the spread of the Zika virus,” said Dr. Richard Hatchett, BARDA’s acting director. “We are working to move medical products through the development pipeline to reach the market as quickly as possible so that doctors and other health care providers have the information they need to guide clinical management,” he added.

The later-flow test is intended to quickly identify recent cases of Zika virus infections using a single drop of blood as a sample, instead of urine — since blood can be analyzed in-house versus sending it to a lab for analysis.

Also funded are two lab diagnostic tests for the virus — as well as $259 million of the $374 million allocated for domestic Zika issues.

To read about the health problems caused by Zika, click here.